The American Physiological Society Press Release

press release logo

APS Contact: APS Communications Office

Email: communications@the-aps.org

Phone: 301.634.7209

Twitter: @APSPhysiology


Is Testosterone Therapy Safe?

Two experts to present opposing data at the APS Physiology and Gender conference

Annapolis, Md. (November 18, 2015)—The increasing use of testosterone replacement therapy to treat reduced testosterone level in older men has been accompanied by growing concerns over its long-term safety. Two studies examining the cardiovascular and kidney disease risks of receiving testosterone will be presented at Cardiovascular, Renal and Metabolic Diseases: Physiology and Gender.

Previous studies published in November 2013 and January 2014 reported increased risk of cardiovascular disease in men who underwent testosterone therapy. Findings from a new review of the literature support the opposite conclusion. “There is no convincing evidence-based data to suggest increased cardiovascular risks with therapy,” stated lead researcher Abdulmaged Traish, PhD. “In fact, the literature is replete with studies demonstrating beneficial effects of testosterone therapy on cardiovascular and overall health,” Traish said.

Traish will present “Testosterone Therapy in Men with Testosterone Deficiency: Advances and Controversies” as part of the symposium “Non-reproductive Actions of Sex Hormones and Receptors—A” Wednesday, Nov. 18, at 10:30 AM EST in Wye Room of the Crowne Plaza Annapolis Hotel.

A separate study to be presented at the conference suggests that using testosterone could cause kidney damage in hypertensive men. Researchers from the University of Tennessee Health Science Center found that giving 6β-hydroxytestosterone (6β-OHT), a compound produced by the body’s metabolism of testosterone, to male mice lacking testosterone made the mice more susceptible to kidney damage from high blood pressure. An earlier study from this group observed that 6β-OHT increased susceptibility to heart damage caused by high blood pressure.

The hormone angiotensin II (Ang II) raises blood pressure. Mice given Ang II steadily for two weeks had kidney damage due to the resulting high blood pressure and the direct effects of Ang II. In this study, castrated mice, which no longer produce testosterone, and mice missing the gene cytochrome P450 1B1 (CYP1B1), whose protein helps break down testosterone, had less Ang II-induced kidney damage compared with non-castrated, normal mice. When the castrated mice and CYP1B1-missing mice were given 6β-OHT, Ang II-associated kidney damage was more severe. “These data suggest that 6β-OHT contributes to impairment of renal (kidney) function and end-organ damage associated with Ang II-induced hypertension in male mice,” according to the researchers. The data also suggest that “CYP1B1 could serve as a novel target for the treatment of renal disease and hypertension,” the researchers wrote.

Lead researcher Ajeeth Pingili, PhD, will present “6β-Hydroxytestosterone, a Cytochrome P450 1B1-Derived Metabolite of Testosterone, Plays an Important Role in Renal Dysfunction Associated with Angiotensin II-Induced Hypertension in Male Mice” as part of the symposium “Non-reproductive Actions of Sex Hormones and Receptors—A” Wednesday, Nov. 18, at 12 PM EST in Wye Room and as part of the poster session “Renal” on Wednesday, Nov. 18, from 1:30 to 2:30 PM in Rhode/Severn Room of the Crowne Plaza Annapolis Hotel.

NOTE TO JOURNALISTS: To read the full abstract or to schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209. Find more research highlights in the APS Press Room.

Physiology is the study of how molecules, cells, tissues and organs function in health and disease. Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.

 


RelatedItems

Raising Dietary Potassium to Sodium Ratio Helps Reduce Heart, Kidney Disease

Released February 21, 2017 - Reducing sodium (salt) in the diet has been recommended to lower blood pressure and the risk of heart disease. However, in a new review article, University of Southern California researchers found that increasing dietary potassium is as important to improving the risk factors for cardiovascular and kidney disease as limiting dietary sodium. The article is published ahead of print in the American Journal of Physiology—Endocrinology and Metabolism.

Nobel Laureate, Esteemed Researchers Participate in APS President’s Symposium

Released April 18, 2017 - APS President Jane Reckelhoff, PhD, of the University of Mississippi Medical Center, has developed an engaging President’s Symposium Series to be presented during the 2017 Experimental Biology meeting in Chicago. Three symposia will focus on the theme “Research Advances in Sex/Gender and Developmental Programming of Chronic Diseases.”

Chromium Picolinate May Lessen Inflammation in Diabetic Nephropathy

Released September 22, 2010 - Taking chromium picolinate may help lessen inflammation associated with kidney disease is the conclusion of a study comparing diabetic mice treated with chromium picolinate with those that received placebo. Mice who received the supplement had lower levels of albuminuria (protein in the urine), an indication of kidney disease. Untreated diabetic mice had marked immunostaining for interleukin 6 (IL-6) and interleukin 17 (IL-1 and moderate immunostaining for indoleamine 2,3-dioxygenase (IDO), an immunoregulatory enzyme that modulates the production of IL-6 and IL-17.

PCOS and Cardiovascular Disease

Released October 14, 2011 - One in 15 women of childbearing age is diagnosed with a disorder commonly referred to as polycystic ovary syndrome (PCOS). The condition is one of the most common causes of women not ovulating and thus causes difficulty in conceiving. Fertility is not the only health consequence these women face, however. PCOS has been associated with an increased risk for cardiovascular disease (CVD), the leading killer of women and men alike. Researcher Sarah Berga, MD provides an update.

From: 
Email:  
To: 
Email:  
Subject: 
Message:

~/Custom.Templates/PressRelease.aspx